Search

This paper reviews the capillary electrophoresis (CE) in 2019. The literatures searched from ISI Web of Science published in 2019 (Jan.1st to Dec.31th) are classified and introduced based on bioanalysis, drug analysis, clinical tests and medical diagnosis, chiral separation, foods tests, other compounds and ion analysis, and the application of capillary electrophoresis-mass spectrometry (CE-MS). International and domestic conferences related to CE and the important research reports are briefly introduced.

This paper reviews the capillary electrophoresis (CE) in 2018. The literatures searched from ISI Web of Science in 2018 (Jan. 1st to Dec. 31th) are classified and introduced based on life science, drugs analysis, chiral separation, medical and clinical tests, CE related instruments improvement, food safety tests and environmental monitoring. Eight conferences and the important reports are introduced briefly. The current domestic and foreign standards of CE method are complemented. In the end, the major domestic CE instruments are listed.

We evaluated the implementation of a cystic fibrosis annual review process in a tertiary paediatric hospital. After implementation, there was demonstrated improvement in an important outcome measure-the use of inhaled mucolytic agents., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)

This paper reviews the capillary electrophoresis (CE) in 2017.The literatures searched from ISI Web of Science published in 2017(Jan.1 to Dec.31) is classified and introduced based on drug analysis, medical and clinical tests, foodsafety tests, environmental monitoring, CE-mass spectrometry technology, chiral analysis, and biological molecules.Seven international and two national conferences are included and important reports are briefly described.Finally, the first prize of the 2017 China Science and Technology Awards, which involved CE applications, is discussed.

We aim to provide a concise, evidence-based framework to assist secondary level, community and acute paediatricians during a 20-60 min annual review of children with neurofibromatosis type 1. This review does not cover all aspects of the disorder. We recognise the importance of an overview of the pathogenesis, molecular genetic testing, clinical manifestations and management; we shall cover some of this briefly, but this is not our focus here. We focus instead on the following areas: (A) what questions should be asked during annual review, (B) what should be included in a focused examination, (C) when to request further investigations and (D) when should a referral be made to tertiary specialists and other members of the multidisciplinary team. Ongoing debates regarding screening remain in certain areas, particularly regarding imaging and ophthalmology follow-up; here we summarise the differing opinions and make a recommendation based on the currently available evidence., (Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/)